Last reviewed 2026-05-28 · How we verify

SB218352_8

GlaxoSmithKline · Phase 2 active Biologic ✓ Verified May 2026

SB218352_8 is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.

SB218352_8 is a compound studied in a clinical trial for the safety and efficacy of pandemic candidate influenza vaccines in the elderly population. The trial, NCT00306995, was conducted by GlaxoSmithKline to evaluate the immunogenicity and reactogenicity of various formulations, including SB218352_8.

Likelihood of approval

18.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
GlaxoSmithKline is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SB218352_8
Sponsor	GlaxoSmithKline
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SB218352_8 CI brief — competitive landscape report
SB218352_8 updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about SB218352_8

What is SB218352_8?

SB218352_8 is a Biologic drug developed by GlaxoSmithKline.

Who makes SB218352_8?

SB218352_8 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is SB218352_8 in?

SB218352_8 is in Phase 2.

Manufacturer: GlaxoSmithKline — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing